Roxee Meds Catalog
Ivermectin 272Mcg, Pyrantel 227Mg
Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.
Veterinary professional?
Data freshness
Roxee is still reviewing source support for this medication profile.
Roxee has safety or ingredient evidence for this medication, but a regulatory product/application match is still pending.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Source timing details
-
Storefront facts:
Source Roxee
| Refreshed May 5, 2026, 10:05 AM UTC
The storefront fact projection used for browse cards and quick facts.
- openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Evidence
Reviewed / Updated / Sources
Reviewed by: Not available
Last reviewed: April 15, 2026
Updated: April 15, 2026, 10:04 AM UTC
- openFDA case USA-USFDACVM-2025-US-070682 · adverse_reaction
Ivermectin 272Mcg, Pyrantel 227Mg
Drug type: Generic ingredient • Generic profile • Source coverage pending
Species: Both
Approval status: Source coverage pending. Roxee has limited supporting content for this record, but no on-page official FDA animal-drug document is linked yet. Treat it as source-limited until the ETL backfill adds official coverage.
Medication Snapshot
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
Ivermectin 272Mcg, Pyrantel 227Mg
Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. Species commonly shown: Both.
Indications / Uses
Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus.
Side Effects
Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose administration interval too long, Drug dose omission, Lack of efficacy (endoparasite) - hookworm.
FAQ
Source Transparency
- Verified source: https://www.roxee.ai/meds/
- Verified source: https://animaldrugsatfda.fda.gov
- Verified source: https://api.fda.gov/animalandveterinary/event.json
- Last refreshed: May 5, 2026, 10:05 a.m.
- Last verified: Apr 15, 2026, 10:04 a.m.
- Validation status: Incomplete
Add to My Pet's Meds
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continuePet Owner Quick Guide
Start here first for the safest next-step summary before the deeper medication detail.
Used for:
Your vet decides this. Here's what owners typically ask/watch for.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
- trouble breathing (1 reports)
- Elevated serum alkaline phosphatase (1 reports)
- Elevated globulins (1 reports)
When to call the vet:
- Repeated vomiting or diarrhea.
- Severe lethargy (hard to wake, very low energy).
- Collapse or fainting.
- Facial swelling or hives.
- Blood in vomit or stool.
What to tell or ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs
Side effects to monitor:
- trouble breathing
- Elevated serum alkaline phosphatase
- Elevated globulins
Most reported reactions:
- Trouble breathing (dyspnea) (1 reports)
- Elevated serum alkaline phosphatase (1 reports)
- Elevated globulins (1 reports)
Emergency warning signs:
- Repeated vomiting or diarrhea.
- Severe lethargy (hard to wake, very low energy).
- Collapse or fainting.
- Facial swelling or hives.
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Grouped by Body System
Most Reported Reactions
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 |
Species coverage: Dog (21) Cat (11)
View detailed reaction table
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Other | Dog | Serious | - | 1 | |
| Digestive | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Digestive | Dog | Non-serious | - | 1 | |
| Digestive | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Behavior | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Skin & allergy | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-070682
Veterinary reference (advanced)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
-
Storefront facts:
Source Roxee
| Refreshed May 5, 2026, 10:05 AM UTC
The storefront fact projection used for browse cards and quick facts.
- openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Diagnosis-code mappings are not available for this medication yet.
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Data Sources & Change Log
Every non-trivial field is expected to include provenance and update timestamps.
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
- monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Clinical, 2026-04-11)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-05-05)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-05-03)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-30)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-29)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-28)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-27)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-26)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-25)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-17)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-04-15)
- side_effects: Top reported reactions (openFDA): INEFFECTIVE, HEARTWORM LARVAE, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Drug dose a… (Official, 2026-02-12)
- usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-21)
- usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-20)
- usage: Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. (Official, 2026-04-19)
- side_effects updated 2026-05-05 10:05 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-05-03 10:05 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-04-30 10:09 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-04-29 10:05 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-04-28 10:05 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-04-27 10:05 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-04-26 10:06 by etl_backfill • Backfilled from existing medication fields
- side_effects updated 2026-04-25 10:05 by etl_backfill • Backfilled from existing medication fields
- monitoring updated 2026-04-21 10:07 by curated_loader • Clinical monitoring context for feline diabetes management.
- usage updated 2026-04-21 10:07 by curated_loader • Usage statement from FDA warning letter and approved-product context.
- drug_profile_type updated 2026-04-21 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
- manufacturer_name updated 2026-04-21 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
- brand_names updated 2026-04-21 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
- approval_reference updated 2026-04-21 10:07 by curated_loader • Official FDA application reference for Senvelgo.
- monitoring updated 2026-04-20 10:08 by curated_loader • Clinical monitoring context for feline diabetes management.
- usage updated 2026-04-20 10:08 by curated_loader • Usage statement from FDA warning letter and approved-product context.
- drug_profile_type updated 2026-04-20 10:08 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
- manufacturer_name updated 2026-04-20 10:08 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
- brand_names updated 2026-04-20 10:08 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
- approval_reference updated 2026-04-20 10:08 by curated_loader • Official FDA application reference for Senvelgo.
Top Reported Reactions (openFDA)
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Skin & allergy.
Showing top 5 for Behavior.
Show more (22)
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Dog (unknown), Male • Drug: MSK, Tablet, chewable, Unknown • Reactions: Sickness, Tiredness (lethargy), Loss of appetite, Staggering • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-075492
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Tablet, chewable
Dog, Beagle, Female, 4 year, 9.979 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Lack of efficacy (endoparasite) - hookworm • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-074016
- Serious AE: No
- Treated For AE: Yes
- Sex: Female
- Age: 4.00 Year
- Weight: 9.979 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Spaniel - King Charles Cavalier, Male, 5 year, 15.422 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal, Frequency: 1 per month • Reactions: Lack of efficacy (bacteria) - Anaplasma • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-073999
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 5.00 Year
- Weight: 15.422 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
- Frequency: 1 per month
Dog, Collie - Border, Male, 10 year, 19.051 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-074655
- Serious AE: No
- Treated For AE: Yes
- Sex: Male
- Age: 10.00 Year
- Weight: 19.051 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Shepherd Dog - Belgian Malinois, Male, 2 year, 28.576 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 tablet per animal, Frequency: 1 per month • Reactions: Lack of efficacy (bacteria) - Anaplasma • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-074299
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 2.00 Year
- Weight: 28.576 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 1 tablet per animal
- Frequency: 1 per month
Dog, Shepherd Dog - German, Female, 4 year, 38.555 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal, Frequency: 1 per month • Reactions: Behavioral disorder (unspecified), Reluctant to move, Pacing, Crying, Nasal discharge • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-075100
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 4.00 Year
- Weight: 38.555 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
- Frequency: 1 per month
Dog, Havanese, Female, 8 year, 3.175 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Intestinal disorder NOS • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-075083
- Serious AE: No
- Treated For AE: Yes
- Sex: Female
- Age: 8.00 Year
- Weight: 3.175 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Sheepdog (unspecified), Female, 8 year, 32.205 kilogram • Drug: MSK, Tablet, Oral, Dose: 272 Microgram per animal, Frequency: 1 per month • Reactions: Vomiting • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-073495
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 8.00 Year
- Weight: 32.205 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet
- Dose: 272 Microgram per animal
- Frequency: 1 per month
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.